New drugs for pediatric epilepsy

Seminars in Pediatric Neurology

Volumn 17, Issue 4, 2010, Pages 214-223

  Chu Shore, Catherine J ^a   Thiele, Elizabeth A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; CLOBAZAM; CYTOCHROME P450; HARKOSERIDE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PRIMIDONE; RETIGABINE; RUFINAMIDE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; ANOREXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONVULSION; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EPILEPSY; FATIGUE; FOCAL EPILEPSY; FOOD; FOOD DRUG INTERACTION; GENERALIZED EPILEPSY; HEADACHE; HUMAN; INFANTILE SPASM; INSOMNIA; IRRITABILITY; LENNOX GASTAUT SYNDROME; LETHARGY; LOW DRUG DOSE; MOTOR DYSFUNCTION; MYOCLONUS SEIZURE; NAUSEA; NONHUMAN; PROTEIN BINDING; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREMOR; TUBEROUS SCLEROSIS; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VOMITING; WEIGHT REDUCTION;

AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUGS, INVESTIGATIONAL; EPILEPSY; HUMANS;

EID: 78650275995     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2010.10.003     Document Type: Review

References (105)

1. Oka E., Ohtsuka Y., Yoshinaga H., et al. Prevalence of childhood epilepsy and distribution of epileptic syndromes: A population-based survey in Okayama, Japan. Epilepsia 2006, 47:626-630.
2. Hauser W.A., Annegers J.F., Kurland L.T. Prevalence of epilepsy in Rochester, Minnesota: 1940-80. Epilepsia 1991, 32:429-445.
3. Murphy C.C., Trevathan E., Yeargin-Allsopp M. Prevalence of epilepsy and epileptic seizures in 10 year old children: Results from the Metropolitan Atlanta Developmental Disabilities Study. Epilepsia 1995, 36:866-872.
4. Shinnar S., Berg A.T., O'Dell C., et al. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol 2000, 48:140-147.
5. Camfield P., Camfield C. Epilepsy can be diagnosed when the first two seizures occur on the same day. Epilepsia 2000, 41:1230-1233.
6. Camfield P., Camfield C. Special considerations for a first seizure in childhood and adolescence. Epilepsia 2008, 49(suppl 1):40-44.
7. Arts W.F., Geerts A.T. When to start drug treatment for childhood epilepsy: The clinical-epidemiological evidence. Eur J Paediatr Neurol 2009, 13:93-101.
8. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002, 1:477-482.
9. Donner E.J., Goodkin H.P. Pediatric epilepsy surgery: looking back while moving forward. Neurology 2010, 74:1756-1757.
10. Dudley R.W., Penney S.J., Buckley D.J. First-drug treatment failures in children newly diagnosed with epilepsy. Pediatr Neurol 2009, 40:71-77.
11. Ackers R., Murray M.L., Besag F.M., et al. Prioritizing children's medicines for research: A pharmaco-epidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007, 63:689-697.
12. Perucca E., Yasothan U., Clincke G., et al. Lacosamide. Nat Rev Drug Discov 2008, 7:973-974.
13. Harris J.A., Murphy J.A. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009, 43:1809-1817.
14. Errington A.C., Stöhr T., Heers C., et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
15. Beyreuther B.K., Freitag J., Heers C., et al. Lacosamide: a review of preclinical properties. CNS Drug Res 2007, 13:21-42.
16. Curia G., Biagini G., Perucca E., et al. Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009, 23:555-568.
17. Ben-Menachem E., Biton V., Jatuzis D., et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
18. Bialer M., Johannessen S.I., Kupferberg H.J., et al. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (Eilat. VIII). Epilepsy Res 2007, 73:1-52.
19. Halasz P., Kälviäinen R., Mazurkiewicz-Beldzińska M., et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
20. Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010, 51:958-967.
21. Wehner T., Bauer S., Hamer H.M., et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009, 16:423-425.
22. Kehne J.H., Kane M., Chaney S.F., et al. Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res 1997, 27:41-54.
23. Kellinghaus C., Berning S., Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009, 14:429-431.
24. Tilz C., Resch R., Hofer T., et al. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010, 51:316-317.
25. Biton V., Rosenfeld W.E., Whitesides J., et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008, 49:418-424.
26. Shields W.D. Diagnosis of infantile spasms, Lennox-Gastaut syndrome, and progressive myoclonic epilepsy. Epilepsia 2004, 45(suppl 5):2-4.
27. Wheless J.W., Vazquez B. Rufinamide: A novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010, 10:1-6.
28. Arroyo S. Rufinamide. Neurotherapeutics 2007, 4:155-162.
29. White H.S., Franklin M.R., Kupferberg H.J., et al. The anticonvulsant profile of Rufinamide (CGP 33101) in rodent seizure models. Epilepsia 2008, 49:1213-1220.
30. Brodie M.J., Rosenfeld W.E., Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
31. Elger C.E., Stefan H., Mann A., et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of Rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010, 88:255-263.
32. Kluger G., Haberlandt E., Kurlemann G., et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010, 17:546-548.
33. Glauser T., Kluger G., Sachdeo R., et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950-1958.
34. Wheless J.W., Conry J., Krauss G., et al. Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies. J Child Neurol 2009, 24:1520-1525.
35. Aldenkamp A.P., Alpherts W.C. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006, 47:1153-1159.
36. Johannessen Landmark C., Johannessen S.I. Pharmacological management of epilepsy: Recent advances and future prospects. Drugs 2008, 68:1925-1939.
37. Marchand M., Fuseau E., Critchley D.J. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. J Pharmacokinet Pharmacodyn 2010, 37:99-118.
38. Willmore L.J., Abelson M.B., Ben-Menachem E., et al. Vigabatrin: 2008 update. Epilepsia 2009, 50:163-173.
39. Petroff O.A., Hyder F., Collins T., et al. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 1999, 40:958-964.
40. Elterman R.D., Shields W.D., Mansfield K.A., et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416-1421.
41. Camposano S.E., Major P., Halpern E., et al. Vigabatrin in the treatment of childhood epilepsy: A retrospective chart review of efficacy and safety profile. Epilepsia 2008, 49:1186-1191.
42. Hancock E.C., Osborne J.P., Edwards S.W. Treatment of infantile spasms. Cochrane Database Syst Rev 2008, 4. CD001770.
43. Lux A.L., Edwards S.W., Hancock E., et al. The United Kingdom infantile spasms Study (UKISS): Comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: A multicentre randomised trial. Lancet Neurol 2005, 4:712-717.
44. Lux A.L., Edwards S.W., Hancock E., et al. The United Kingdom Infantile Spasms Study: Comparing vigabatrin with prednisolone or tetracosactide at 14 days: A multicentre, randomised controlled trial. Lancet 2004, 364:1773-1778.
45. Darke K., Edwards S.W., Hancock E., et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: A multi-centre randomised trial. Arch Dis Child 2010, 95:382-386.
46. Cohen-Sadan S., Kramer U., Ben-Zeev B., et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur J Neurol 2009, 16:482-487.
47. Hemming K., Maguire M.J., Hutton J.L., et al. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 2008, 3. CD007302.
48. French J.A., Mosier M., Walker S., et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 1996, 46:54-61.
49. Dean C., Mosier M., Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999, 40:74-82.
50. Kalviainen R., Nousiainen I., Mäntyjärvi M., et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999, 53:922-926.
51. Wild J.M., Martinez C., Reinshagen G., et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999, 40:1784-1794.
52. Miller N.R., Johnson M.A., Paul S.R., et al. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings. Neurology 1999, 53:2082-2087.
53. Krauss G.L. Evaluating risks for vigabatrin treatment. Epilepsy Curr 2009, 9:125-129.
54. Pearl P.L., Vezina L.G., Saneto R.P., et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009, 50:184-194.
55. Milh M., Villeneuve N., Chapon F., et al. Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol 2009, 24:305-315.
56. Wheless J.W., Carmant L., Bebin M., et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009, 50:195-205.
57. Lange W., Geissendörfer J., Schenzer A., et al. Refinement of the binding site and mode of action of the anticonvulsant retigabine on KCNQ K+ channels. Mol Pharmacol 2009, 75:272-280.
58. Wickenden A.D., Yu W., Zou A., et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000, 58:591-600.
59. Czuczwar P., Wojtak A., Cioczek-Czuczwar A., et al. Retigabine: The newer potential antiepileptic drug. Pharmacol Rep 2010, 62:211-219.
60. Porter R.J., Partiot A., Sachdeo R., et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
61. Bialer M., Johannessen S.I., Levy R.H., et al. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (Eilat IX). Epilepsy Res 2009, 83:1-43.
62. Kurahashi H., Wang J.W., Ishii A., et al. Deletions involving both KCNQ2 and CHRNA4 present with benign familial neonatal seizures. Neurology 2009, 73:1214-1217.
63. Bellini G., Miceli F., Soldovieri M.V. Benign familial neonatal seizures. GeneReviews 2010, University of Washington, Seattle, WA. B. Stephens, R.A. Pagan, C.R. Dolan (Eds.).
64. Rogawski M.A. Brivaracetam: A rational drug discovery success story. Br J Pharmacol 2008, 154:1555-1557.
65. Custer K.L., Austin N.S., Sullivan J.M., et al. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006, 26:1303-1313.
66. Kasteleijn-Nolst Trenite D.G., Genton P., Parain D., et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007, 69:1027-1034.
67. French J.A., Von Rosenstiel P. Efficacy and tolerability of 5 20, 50 mg/day Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007, 48:400. Brivaracetam N01193 Study Group.
68. van Paesschen W. Efficacy and tolerability of 50 and 150 mg/day Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy. Epilepsia 2007, 48:329. b.o.t.B.N.S.G.,.
69. Accessed November 1, 2010. http://professionals.epilepsy.com/page/announce_42909.html.
70. Brodsky A., von Rosenstiel P. Safety and tolerability of Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2008, 48:342.
71. Accessed November 10, 2010. http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1418334_EN.asp.
72. McKernan R.M., Rosahl T.W., Reynolds D.S., et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000, 3:587-592.
73. Ng Y.T., Collins S.D. Clobazam. Neurotherapeutics 2007, 4:138-144.
74. Michael B. Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 2008, 16. CD004154.
75. Clobazam has equivalent efficacy to carbamazepinephenytoin as monotherapy for childhood epilepsy: Canadian Study Group for Childhood Epilepsy. Epilepsia 1998, 39:952-959.
76. Koeppen D., Baruzzi A., Capozza M., et al. Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study. Epilepsia 1987, 28:495-506.
77. Keene D.L., Whiting S., Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990, 17:317-319.
78. Dube C.M., Ravizza T., Hamamura M., et al. Epileptogenesis provoked by prolonged experimental febrile seizures: Mechanisms and biomarkers. J Neurosci 2010, 30:7484-7494.
79. Blumenfeld H., Klein J.P., Schridde U., et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008, 49:400-409.
80. Riikonen R.S. Favourable prognostic factors with infantile spasms. Eur J Paediatr Neurol 2010, 14:13-18.
81. Goh S., Kwiatkowski D.J., Dorer D.J., et al. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 2005, 65:235-238.
82. Liukkonen E., Kantola-Sorsa E., Paetau R., et al. Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome. Epilepsia 2010, 51:2023-2032.
83. Jaseja H. The dilemma on treatment of the EEG: A justified perspective. Epilepsy Behav 2009, 16:561-562.
84. Chu-Shore C.J., Major P., Camposano S., et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010, 51:1236-1241.
85. Fastenau P.S., Johnson C.S., Perkins S.M., et al. Neuropsychological status at seizure onset in children: Risk factors for early cognitive deficits. Neurology 2009, 73:526-534.
86. Chiron C., Dulac O., Pons G. Antiepileptic drug development in children: Considerations for a revisited strategy. Drugs 2008, 68:17-25.
87. Berg A., Berkovic S.F., Brodie M.J., et al. Revised terminology and concepts for organization of the epilepsies: Report of the commission on classification and terminology ILAE, Accessed July 9, 2010. http://www.ilae-epilepsy.org/visitors.documents/classificationsummaryreportwebaug2009.
88. Glauser T.A., Cnaan A., Shinnar S., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
89. Duchowny M., Pellock J.M., Graf W.D., et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children: Lamictal Pediatric Partial Seizure Study Group. Neurology 1999, 53:1724-1731.
90. Appleton R., Fichtner K., LaMoreaux L., et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study: Gabapentin Paediatric Study Group. Epilepsia 1999, 40:1147-1154.
91. Elterman R.A., Glauser T.A., Wyllie E., et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999, 52:1338-1344.
92. Glauser T.A., Nigro M., Sachdeo R., et al. Adjunctive therapy with oxcarbazepine in children with partial seizures: The Oxcarbazepine Pediatric Study Group. Neurology 2000, 54:2237-2244.
93. Glauser T.A., Ayala R., Elterman R.D., et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660.
94. Sachdeo R.C., Glauser T.A., Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999, 52:1882-1887.
95. Chiron C., Marchand M.C., Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356:1638-1642.
96. Motte J., Trevathan E., Arvidsson J.F., et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome in Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997, 337:1807-1812.
97. Rosman N.P., Colton T., Labazzo J., et al. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N Engl J Med 1993, 329:79-84.
98. Wheless J.W., Clarke D.F., Arzimanoglou A., et al. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007, 9:353-412.
99. Johannessen S.I., Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed?. Clin Pharmacokinet 2006, 45:1061-1075.
100. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006, 45:351-363.
101. Perucca E., Cloyd J., Critchley D., et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008, 49:1123-1141.
102. Greenblatt D.J., Shader R.I. Pharmacokinetic aspects of anxiolytic drug therapy. Can J Neurol Sci 1980, 7:269-270.
103. Riss J., Cloyd J., Gates J., et al. Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics. Acta Neurol Scand 2008, 118:69-86.
104. Rey E., Pons G., Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet 1992, 23:267-278.
105. Tedeschi G., Riva R., Baruzzi A. Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients. Br J Clin Pharmacol 1981, 11:619-622.